Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in parkinson disease

JAMA Neurology

Volumn 73, Issue 10, 2016, Pages 1217-1224

  Davis, Marie Y ^a,b   Johnson, Catherine O ^b   Leverenz, James B ^c   Weintraub, Daniel ^d   Trojanowski, John Q ^d   Chen Plotkin, Alice ^d   Van Deerlin, Vivianna M ^d   Quinn, Joseph F ^e,f   Chung, Kathryn A ^e,f   Peterson Hiller, Amie L ^e,f   Rosenthal, Liana S ^g   Dawson, Ted M ^g   Albert, Marilyn S ^g   Goldman, Jennifer G ^h   Stebbins, Glenn T ^h   Bernard, Bryan ^h   Wszolek, Zbigniew K ⁱ   Ross, Owen A ^j   Dickson, Dennis W ^j   Eidelberg, David ^k,l   Mattis, Paul J ^k,l   Niethammer, Martin ^k   Yearout, Dora ^a,b   Hu, Shu Ching ^a,b   Cholerton, Brenna A ^a,b   Smith, Megan ^m   Mata, Ignacio F ^a,b   Montine, Thomas J ^b   Edwards, Karen L ^m   Zabetian, Cyrus P ^a,b   more..

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j MAYO GRADUATE SCHOOL   (United States)

^k FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^l School of Medicine ^*  (United States)

^m University of California   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; GLUCOSYLCERAMIDASE;

ABNORMAL POSTURE; AGE DISTRIBUTION; AGED; ARTICLE; COGNITION ASSESSMENT; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GAIT DISORDER; GBA GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY;

AGED; COGNITIVE DYSFUNCTION; DEMENTIA; DISEASE PROGRESSION; FEMALE; GLUCOSYLCERAMIDASE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 84998694373     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.2245     Document Type: Article

References (36)

1. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328 (3):176-183.
2. Poewe W. The need for neuroprotective therapies in Parkinson's disease: a clinical perspective. Neurology. 2006;66(10)(suppl 4):S2-S9.
3. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000;15(3):479-484.
4. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661.
5. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain. 2013;136(pt 2):392-399.
6. Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2014.
7. Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C. Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol Aging. 2016;37: 209.e1-209.e7.
8. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750.
9. Pankratz N, Beecham GW, DeStefano AL, et al; PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370-384.
10. Goetz CG, Tilley BC, Shaftman SR, et al; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15): 2129-2170.
11. Gibb WR, Lees AJ. The relevanceofthe Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6): 745-752.
12. Goetz CG, Stebbins GT, Tilley BC. Calibration of Unified Parkinson's Disease Rating Scale scores to Movement Disorder Society-Unified Parkinson's Disease Rating Scale scores. Mov Disord. 2012;27 (10):1239-1242.
13. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649-2653.
14. Mata IF, Leverenz JB, Weintraub D, et al. GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2016;31(1):95-102.
15. Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405-1412.
16. Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70(7):852-858.
17. Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of Excellence Clinical Consortium: study design and baseline cohort characteristics. J Parkinsons Dis. 2013;3(2):205-214.
18. Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012;27(9):1129-1136.
19. Bates DMM, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1-48.
20. R Foundation for Statistical Computing. R: A language and environment for statistical computing. https://www.R-project.org/. Published 2015. Accessed January 15, 2016.
21. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson's Disease Rating Scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord. 2013;28(5):668-670.
22. Kelly VE, Johnson CO, McGough EL, et al. Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. Parkinsonism Relat Disord. 2015;21(7):692-697.
23. Nichols WC, Pankratz N, Marek DK, et al; Parkinson Study Group-PROGENI Investigators. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72(4):310-316.
24. Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752-757.
25. Horowitz M, Pasmanik-Chor M, Ron I, Kolodny EH. The enigmaofthe E326K mutation in acid β-glucocerebrosidase. Mol Genet Metab. 2011;104 (1-2):35-38.
26. Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging. 2009;30(9):1515-1517.
27. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132(pt 7):1783-1794.
28. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett. 2009; 452(2):87-89.
29. Lesage S, Anheim M, Condroyer C, et al; French Parkinson's Disease Genetics Study Group. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011;20(1):202-210.
30. Torralba MA, Pérez-Calvo JI, Pastores GM, Cenarro A, Giraldo P, Pocoví M. Identification and characterization of a novel mutation c.1090G>T (G325W) and nine common mutant alleles leading to Gaucher disease in Spanish patients. Blood Cells Mol Dis. 2001;27(2):489-495.
31. Montfort M, Chabás A, Vilageliu L, Grinberg D. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and "modifier" polymorphisms. Hum Mutat. 2004;23(6):567-575.
32. Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015;138(pt 9):2648-2658.
33. Keatinge M, Bui H, Menke A, et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum Mol Genet. 2015;24(23):6640-6652.
34. Du TT, Wang L, Duan CL, et al. GBA deficiency promotes CA/α-synSNuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy. 2015;11(10):1803-1820.
35. Uemura N, Koike M, Ansai S, et al. Viable neuronopathic Gaucher disease model inMedaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein. PLoS Genet. 2015;11(4):e1005065.
36. Awad O, Sarkar C, Panicker LM, et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet. 2015;24(20):5775-5788.